Vasopressin for Vasoplegic Shock Market

Vasoplegia is a type of syndrome that involves pathologically low systemic vascular resistance. It further leads to reduced blood pressure amid presence of a raised cardiac output. Vasopressin is an antidiuretic hormone directed to be used for the treatment and prevention of postoperative abdominal distention in abdominal roentgenography. lt is mosty used as an intensive care medicine.Vasopressin infusion efficiently increases systemic vascular resistance and arterial pressure while improving survival chances in patients. Additionally, it decreases catecholamine vasopressors requirements in the patient with or at the risk of vasoplegic syndrome after cardiac surgery.
Vasopressin for Vasoplegic Shock Market contains market size and forecasts of Vasopressin for Vasoplegic Shock in Global, including the following market information:
Global Vasopressin for Vasoplegic Shock Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Vasopressin for Vasoplegic Shock market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravenous Injection Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Vasopressin for Vasoplegic Shock include Endo International, AMOMED Pharma, La Jolla Pharmaceutical Company, Pfizer, Ferring Pharmaceuticals, Fresenius Kabi, Astellas Pharma and Eagle Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Vasopressin for Vasoplegic Shock companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Vasopressin for Vasoplegic Shock Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Vasopressin for Vasoplegic Shock Market Segment Percentages, by Type, 2021 (%)
Intravenous Injection
Intramuscular Injection
Subcutaneous Injection
Global Vasopressin for Vasoplegic Shock Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Vasopressin for Vasoplegic Shock Market Segment Percentages, by Application, 2021 (%)
Sepsis
Post Cardiac Surgery
Others
Global Vasopressin for Vasoplegic Shock Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Vasopressin for Vasoplegic Shock Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Vasopressin for Vasoplegic Shock revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Vasopressin for Vasoplegic Shock revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Endo International
AMOMED Pharma
La Jolla Pharmaceutical Company
Pfizer
Ferring Pharmaceuticals
Fresenius Kabi
Astellas Pharma
Eagle Pharmaceuticals